We are live on ! Find out more

Axogen

AXGN

Market cap $2.27B

42.16 USD

+0.31

0.74%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

42.16

0.00

0%

1 day

0.74%

5 days

-9.78%

1 month

-13.04%

3 months

-0.47%

6 months

30.57%

Year to date

36%

1 year

150.95%

5 years

155.36%

10 years

400.71%

About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.

Employees: 622

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 66.7%

Negative 8.3%

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Schaeffers Research

2 Medical-Device Stocks Lighting Up the Options Pits

Medical-device stocks Cooper Companies Inc (NASDAQ:COO) and Axogen Inc (NASDAQ:AXGN) are both sharply lower following separate company developments, and options traders are chiming in.

2 Medical-Device Stocks Lighting Up the Options Pits

Axogen, Inc. (AXGN) M&A Call Transcript

Axogen, Inc. (AXGN) M&A Call Transcript

Axogen, Inc. (AXGN) M&A Call Transcript

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up to an additional 736,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Axogen from the proposed offering, before deducting underwriters' discounts and commissions and other offering expenses payable by Axogen, are expected to be approximately $208.7 million (assuming no exercise of the underwriters' option to purchase additional shares). The proposed offering is expected to close on September 11, 2026, subject to the satisfaction of customary closing conditions.

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla.

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

AxoGen Q2 Earnings Call Highlights

AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.

AxoGen Q2 Earnings Call Highlights

Zacks Investment Research

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™